
### 2019 Novel Coronavirus (COVID-19)

# South Dakota Department of Health

June 24, 2021



We will begin in just a few moments. Thanks!



This is an **emerging**, **rapidly evolving situation**. Information in this presentation is current as of June 23, 2021. Please check the South Dakota Department of Health website for the most current information and guidance.

**COVID.sd.gov** 



# Agenda


- Situation Update
- Laboratory Guidance
- Infection Prevention
- Community Mitigation
- Supply Chain Management
- On-going Communications
- Q&A Session

## Coronavirus Situation (as of June 23, 2021)


- International
  - 178,837,204 confirmed cases
  - 3,880,450 deaths deaths
- United States (50 states + DC)
  - 33,382,705 confirmed cases
  - 599,751 deaths
- South Dakota
  - 124,468 confirmed and probable cases
  - 2,029 deaths
  - 122,277 recovered cases



# **Epidemiologic "Epi" Curve of COVID-19 Cases,** by Date Reported to SD-DOH




## **COVID-19 Case Map, by County**



Community Spread	Number of Counties
None	33
Minimal	24
Moderate	9
Substantial	0



# SOUTH DAKOTA % Coverage by Age Group



12-14y15-19y20-24y25-29y30-34y35-39y40-44y45-49y50-54y55-59y60-64y65-69y70-74y75-79y 80+y

Not intended for press or for reporting purposes.

## **General Testing Recommendations**

Medical providers are recommended to test individuals (1) identified as a close contact to a person with COVID-19 or (2) signs and symptoms compatible with COVID-19 infection, including:

- Fever or chills
- Cough
- Shortness of breath or difficulty breathing
- Fatigue
- Muscle or body aches
- Headache
- New loss of taste or smell
- Sore throat
- Congestion or runny nose
- Nausea or vomiting
- Diarrhea

https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html



## Reporting COVID-19 Tests to SD-DOH

- Reminder: Coronavirus respiratory syndromes are a Category I disease
- Report <u>immediately</u> on suspicion of disease
- Reporting mechanisms:
  - Electronic Laboratory Report (ELR) HL7 message to SD Health Link (health information exchange)
  - Flat file (CSV) Secure email
  - Disease reporting website <u>sd.gov/diseasereport</u>
  - Fax 605.773.5509

# **Breakthrough, Variant, and Potential Reinfection Cases**

Breakthrough Cases	n
Cases	388
Hospitalized	57
Died	12

Variant Cases	n
Cases	191
Hospitalized	5
Died	1

Potential Reinfection	n
Cases	215
Hospitalized	26
Died	9

COVID-19 Variant Data under *Tables* tab: <a href="https://doh.sd.gov/COVID/Dashboard.aspx">https://doh.sd.gov/COVID/Dashboard.aspx</a>

As of June 23, 2021



# COVID-19 Vaccination Coverage and Intent Among Adults Aged 18–39 Years — United States, March–May 2021

			Weighted % (95% CI <sup>†</sup> )				
			Vaccination status	Vac	Vaccination and intent status		
Characteristic	Total no.*	% (95% CI)	Vaccinated (N = 1,022)	Vaccinated or definitely planning to get vaccinated (N = 1,521)	Unsure or probably will get vaccinated (N = 562)	_	
Total	2,726	100 (99.9–100.0)	34.0 (31.9-36.2)	51.8 (49.3-54.4)	23.2 (21.1–25.4)	24.9 (22.9–27.1)	
Education							
Less than high school	200	13.1 (11.2-15.2)	16.2 (11.1-22.5) <sup>5</sup>	32.4 (25.0-40.5) <sup>5</sup>	31.8 (24.4-39.8)5	35.8 (27.3-45.1) <sup>5</sup>	
High school diploma or equivalent	533	28.0 (25.6-30.4)	23.6 (19.3-28.3)5	40.7 (35.6-45.9) <sup>5</sup>	28.5 (24.0-33.3)5	30.8 (26.4-35.6) <sup>5</sup>	
Some college	932	28.9 (26.9-30.9)	33.6 (30.0-37.4) <sup>5</sup>	49.9 (46.0-53.8) <sup>5</sup>	24.6 (21.2-28.4)5	25.5 (22.2-29.0) <sup>§</sup>	
Bachelor's degree or higher (Ref)	1,061	30.0 (28.0-32.1)	51.8 (48.5-55.2)	72.6 (69.4–75.7)	13.3 (11.1-15.7)	14.1 (11.7-16.8)	
Household income, \$							
<24,999	420	19.1 (16.9-21.4)	21.0 (16.2-26.3)5	36.2 (30.0-42.7) <sup>5</sup>	27.0 (21.8-32.7)5	36.8 (30.9-42.9)§	
25,000-49,999	604	22.2 (20.2-24.2)	28.0 (24.0-32.3)5	43.8 (39.1-48.7)5	26.3 (21.4-31.7)5	29.9 (25.4-34.6)5	
50,000-74,999	537	18.4 (16.7-20.1)	35.3 (30.4-40.5) <sup>5</sup>	50.5 (45.3-55.7) <sup>§</sup>	24.7 (20.3-29.6)	24.7 (20.3-29.6) <sup>5</sup>	
≥75,000 (Ref)	1,165	40.3 (38.0-42.7)	42.9 (39.5-46.4)	64.2 (60.9-67.5)	19.1 (16.3-22.1)	16.7 (14.5-19.1)	

70/wr/mm7025e2.htm

Not intended for press or for reporting purposes.



## COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy — Eight Integrated Health Care Organizations, United States, December 14, 2020-May 8, 2021

TABLE. Receipt of ≥1 dose,\* initiation,† and completion§ of COVID-19 vaccination during pregnancy among pregnant women, by selected characteristics and by vaccine type — Vaccine Safety Datalink, United States, December 14, 2020-May 8, 2021

				140. (70")				
		Vaccine**						
Total	Receipt of	Total		Pfizer-BioNTech		Moderna		
population	≥1 dose*	Initiation <sup>†</sup>	Completion§	Initiation <sup>†</sup>	Completion§	Initiation <sup>†</sup>	Completion§	Janssen
135,968 (100)	22,197 (16.3)	7,154 (5.3)	15,043 (11.1)	3,658 (2.7)	8,226 (6.0)	3,496 (2.6)	5,992 (4.4)	825 (0.6)
18,882 (13.9)	1,044 (5.5)	458 (2.4)	586 (3.1)	195 (1.0)	307 (1.6)	263 (1.4)	240 (1.3)	39 (0.2)
83,335 (61.3)	13,478 (16.2)	4,368 (5.2)	9,110 (10.9)	2,203 (2.6)	4,986 (6.0)	2,165 (2.6)	3,638 (4.4)	486 (0.6)
33,751 (24.8)	7,675 (22.7)	2,328 (6.9)	5,347 (15.8)	1,260 (3.7)	2,933 (8.7)	1,068 (3.2)	2,114 (6.3)	300 (0.9)
46,245 (34.0)	9,105 (19.7)	2,653 (5.7)	6,452 (14.0)	1,456 (3.1)	3,645 (7.9)	1,197 (2.6)	2,491 (5.4)	316 (0.7)
10,729 (7.9)	644 (6.0)	242 (2.3)	402 (3.7)	124 (1.2)	215 (2.0)	118 (1.1)	161 (1.5)	26 (0.2)
44,673 (32.9)	5,312 (11.9)	1,893 (4.2)	3,419 (7.7)	804 (1.8)	1,689 (3.8)	1,089 (2.4)	1,529 (3.4)	201 (0.4)
19,597 (14.4)	4,834 (24.7)	1,512 (7.7)	3,322 (17.0)	834 (4.3)	1,880 (9.6)	678 (3.5)	1,252 (6.4)	190 (1.0)
6,292 (4.6)	990 (15.7)	350 (5.6)	640 (10.2)	174 (2.8)	352 (5.6)	176 (2.8)	243 (3.9)	45 (0.7)
8,432 (6.2)	1,312 (15.6)	504 (6.0)	808 (9.6)	266 (3.1)	445 (5.3)	238 (2.8)	316 (3.7)	47 (0.6)
	135,968 (100) 18,882 (13.9) 83,335 (61.3) 33,751 (24.8) 46,245 (34.0) 10,729 (7.9) 44,673 (32.9) 19,597 (14.4) 6,292 (4.6)	population ≥1 dose*  135,968 (100) 22,197 (16.3)  18,882 (13.9) 1,044 (5.5) 83,335 (61.3) 13,478 (16.2) 33,751 (24.8) 7,675 (22.7)  46,245 (34.0) 9,105 (19.7) 10,729 (7.9) 644 (6.0) 44,673 (32.9) 5,312 (11.9) 19,597 (14.4) 4,834 (24.7) 6,292 (4.6) 990 (15.7)	Total population         Receipt of ≥1 dose*         Initiation <sup>†</sup> 135,968 (100)         22,197 (16.3)         7,154 (5.3)           18,882 (13.9)         1,044 (5.5)         458 (2.4)           83,335 (61.3)         13,478 (16.2)         4,368 (5.2)           33,751 (24.8)         7,675 (22.7)         2,328 (6.9)           46,245 (34.0)         9,105 (19.7)         2,653 (5.7)           10,729 (7.9)         644 (6.0)         242 (2.3)           44,673 (32.9)         5,312 (11.9)         1,893 (4.2)           19,597 (14.4)         4,834 (24.7)         1,512 (7.7)           6,292 (4.6)         990 (15.7)         350 (5.6)	Total population         Receipt of ≥1 dose*         Initiation†         Completion§           135,968 (100)         22,197 (16.3)         7,154 (5.3)         15,043 (11.1)           18,882 (13.9)         1,044 (5.5)         458 (2.4)         586 (3.1)           83,335 (61.3)         13,478 (16.2)         4,368 (5.2)         9,110 (10.9)           33,751 (24.8)         7,675 (22.7)         2,328 (6.9)         5,347 (15.8)           46,245 (34.0)         9,105 (19.7)         2,653 (5.7)         6,452 (14.0)           10,729 (7.9)         644 (6.0)         242 (2.3)         402 (3.7)           44,673 (32.9)         5,312 (11.9)         1,893 (4.2)         3,419 (7.7)           19,597 (14.4)         4,834 (24.7)         1,512 (7.7)         3,322 (17.0)           6,292 (4.6)         990 (15.7)         350 (5.6)         640 (10.2)	Total population ≥1 dose*	Total population         Receipt of ≥1 dose*         Initiation†         Completion§         Initiation†         Completion§           135,968 (100)         22,197 (16.3)         7,154 (5.3)         15,043 (11.1)         3,658 (2.7)         8,226 (6.0)           18,882 (13.9)         1,044 (5.5)         458 (2.4)         586 (3.1)         195 (1.0)         307 (1.6)           83,335 (61.3)         13,478 (16.2)         4,368 (5.2)         9,110 (10.9)         2,203 (2.6)         4,986 (6.0)           33,751 (24.8)         7,675 (22.7)         2,328 (6.9)         5,347 (15.8)         1,260 (3.7)         2,933 (8.7)           46,245 (34.0)         9,105 (19.7)         2,653 (5.7)         6,452 (14.0)         1,456 (3.1)         3,645 (7.9)           10,729 (7.9)         644 (6.0)         242 (2.3)         402 (3.7)         124 (1.2)         215 (2.0)           44,673 (32.9)         5,312 (11.9)         1,893 (4.2)         3,419 (7.7)         804 (1.8)         1,689 (3.8)           19,597 (14.4)         4,834 (24.7)         1,512 (7.7)         3,322 (17.0)         834 (4.3)         1,880 (9.6)           6,292 (4.6)         990 (15.7)         350 (5.6)         640 (10.2)         174 (2.8)         352 (5.6)	Total population         Receipt of population ≥1 dose*         Total Initiation†         Completion§         Initiation†         Completion§         Initiation†         Completion§         Initiation†         Mode of population           135,968 (100)         22,197 (16.3)         7,154 (5.3)         15,043 (11.1)         3,658 (2.7)         8,226 (6.0)         3,496 (2.6)           18,882 (13.9)         1,044 (5.5)         458 (2.4)         586 (3.1)         195 (1.0)         307 (1.6)         263 (1.4)           83,335 (61.3)         13,478 (16.2)         4,368 (5.2)         9,110 (10.9)         2,203 (2.6)         4,986 (6.0)         2,165 (2.6)           33,751 (24.8)         7,675 (22.7)         2,328 (6.9)         5,347 (15.8)         1,260 (3.7)         2,933 (8.7)         1,068 (3.2)           46,245 (34.0)         9,105 (19.7)         2,653 (5.7)         6,452 (14.0)         1,456 (3.1)         3,645 (7.9)         1,197 (2.6)           10,729 (7.9)         644 (6.0)         242 (2.3)         402 (3.7)         124 (1.2)         215 (2.0)         118 (1.1)           44,673 (32.9)         5,312 (11.9)         1,893 (4.2)         3,419 (7.7)         804 (1.8)         1,689 (3.8)         1,089 (2.4)           1	Total population ≥1 dose*



# COVID-19 Vaccination Coverage Among Adults — United States, December 14, 2020–May 22, 2021

By May 22, 2021, 57% of people 18 or older in the U.S. had received 1 or more COVID-19 vaccine doses

Vaccination coverage was:

Highest among people 65 and older (80%)



Lowest among people 18-29 (38%)



Improving vaccination coverage, especially among younger people, is critical to reducing COVID-19 cases, hospitalizations, and deaths

CDC.GOV

bit.ly/MMWR61821

WWWR

% Population Vaccinated in South Dakota				
20–29 Years	30.8%			
65+ Years	82.2%			


https://www.cdc.gov/mmwr/volumes/70/wr/mm7025e1.htm

?s\_cid=mm7025e1\_x

Not intended for press or for reporting purposes.



# Cases by Vaccination Status in South Dakota – March 10, 2020 - June 21





## **Selected CDC Updates**

Available at: <a href="https://www.cdc.gov/coronavirus/2019-ncov/whats-new-all.html">https://www.cdc.gov/coronavirus/2019-ncov/whats-new-all.html</a>

Frequently Asked Questions about COVID-19 Vaccination: <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/faq.html</a>

COVID-19 Vaccines While Pregnant or Breastfeeding: <a href="https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html">https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html</a>

Risk for COVID-19 Infection, Hospitalization, and Death By Race/Ethnicity: <a href="https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html">https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html</a>



# **Laboratory Guidance**



## Abbott BinaxNOW & ID Now Resources

- SDDOH continues to provide Abbott testing resources.
- SDDOH has placed Abbott resources in the following:
  - K-12 schools
  - Colleges and universities
  - Correctional facilities
  - Long-term care facilities
  - Critical access hospitals
  - Residential service providers to vulnerable populations
  - FQHCs and other facilities that serve vulnerable populations
- SDDOH continues to accept requests for Abbott resources. Please contact the SDPHL for details:
  - Laurie.Gregg@state.sd.us







# State-Supplied Collection and Test Kits

- SDDOH and the federal government have placed specimen collection supplies and test kits throughout South Dakota.
- Facilities that no longer have use for <u>state-provided</u> collection supplies and test kits are asked to consider the following:
  - Test kits:
    - Unexpired and unopened: Return to SDDOH
    - Unexpired and opened: Do not return to SDDOH; use or destroy
    - Expired and unopened: Do not return to SDDOH; destroy
    - Expired and opened: Do not return to SDDOH; destroy
  - Surveillance specimen collection kits and other specimen collection materials:
    - Resources can be repurposed for other testing needs
    - Unopened kits can be returned to SDDOH
- Please contact <u>Laurie.Gregg@state.sd.us</u> with questions.



# SARS-CoV-2 Surveillance and Sequencing

- Monthly SARS-CoV-2 testing in South Dakota continues to decrease significantly.
- Despite the reduction in testing, **SDPHL continues to request SARS-CoV-2-positive specimens for variant analysis.**
- Continued surveillance is critical to track the spread of SARS-CoV-2 variants including the Delta variant which is projected to become the next dominant variant in the United States.

#### **B.1.617.2** (<u>Pango lineage</u> ☐ )<sup>a</sup>

Spike Protein Substitutions: T19R, (G142D\*), 156del, 157del, R158G, L452R, T478K, D614G, P681R, D950N

Name (Nextstrain )b: 20A/S:478K

WHO Label: Delta

First Identified: India


#### Attributes:

- Increased transmissibility<sup>29</sup>
- Potential reduction in neutralization by some EUA monoclonal antibody treatments 7, 14
- Potential reduction in neutralization by post-vaccination sera <sup>21</sup>



## COVID Data Tracker

- The SARS-CoV-2 lineage in South Dakota is still B.1.1.7 (UK variant).
- B.1.617.2 (Delta variant) is rapidly spreading through HHS Region
   8 which includes SD, ND, MT, CO, UT, and WY
- The South Dakota Public Health Laboratory has not detected the Delta Variant to-date.
- However, specimen submissions to the SDPHL have decreased significantly.
- SDPHL asks that our healthcare partners ensure that residual specimens from individuals that test positive for SARS-CoV-2 are submitted promptly to the SDPHL for sequencing.
- If a patients tests positive for SARS-CoV-2 using an antigen test, or any other test that does not require swab collection in VTM, please collect a second swab sample in VTM for sequencing.





## **Infection Prevention**



#### Final month to participate in the Infection Prevention Learning Needs Assessment!

Our goal of 2,000 responses is near. Please help us by promoting this survey to:

- \*Teachers and Education staff
- \*Environmental Service and cleaning providers
- \*EMS, First Responders & Law Enforcement
- \*Dialysis nursing staff
- \*Community support staff members

WE ARE **PROJECT FIRSTLINE** 



Scan QR Code below for link to survey:



### Foundation for Medical Care





For everyone that has participated, we appreciate your input!

Not intended for press or for reporting purposes.

### **Save the Date**

October 7-8, 2021

2021 South Dakota Infection Control
Conference – Virtual Event

For more information, please visit webpage below!




https://und.edu/conferences/sd-infection-control/



# **Community Mitigation**






## **Dashboard**



PCR Test Positivity Rate: This rate is equal to the number of positive PCR tests divided by total PCR tests, within the specified period of time. Date range includes last full day (24 hours) captured in the data set.



14-Day Trend of Confirmed Cases by Date Reported to SD-DOH: This graph shows the trend (increasing or decreasing) of COVID-19 confirmed cases (persons who meet the national surveillance case definition case for COVID-19) at the state or county level

Daily Rate of Total Cases, Last 7 Days
5/14/2021 - 5/20/2021
4.11

Daily Case Rate per Capita

Rate of Total Cases, Cumulative
3/10/2020 - 5/20/2021
14,047
Case Rate per Capita



# **Supply Chain Management**



# **PPE Request Procedure**

#### All requests for PPE from DOH must be:

- Emailed to <u>COVIDResourceRequests@state.sd.us</u>,
- Faxed to **605.773.5942**, or
- Called in to 605.773.3048 to ensure prioritization and coordination of requests.
- <u>Do not</u> duplicate your request by using all three means of communication.
- Any requests received through any other email or number will all be directed to email <u>COVIDResourceRequests@state.sd.us</u> OR call 605.773.3048 and requesting entities must provide information regarding their current facility status.

# **On-going Communication**



## Helpful sources of information:

covid.sd.gov

coronavirus.gov

SD COVID-19 Help Line: 800-997-2880





### **Communications**

SD-HAN: <u>sdhan.sd.gov</u>

Epi Listserv

Lab Listserv

HAI Listserv

OLC Listserv

Visit **covid.sd.gov** to subscribe





## **Questions?**

Follow-up after the webinar

**COVID Helpline: 800-997-2880** 

**Epidemiology:** 605-773-3737

Laboratory: 605-773-3368

**COVID.sd.gov** 

CDC Project Firstline Infection Control Survey.
Scan QR Code below



